|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.965 USD | +2.24% |
|
+2.14% | +14.80% |
| 04-25 | OncoCyte Corporation announced that it has received $15.807655 million in funding | CI |
| 04-16 | Broadwood Capital, Inc. Engages with OncoCyte Corporation | CI |
OncoCyte Corporation reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 0.958 million compared to USD 2.2 million a year ago. Net loss was USD 72.9 million compared to USD 64.1 million a year ago.
Basic loss per share from continuing operations was USD 3.4 compared to USD 9.8 a year ago. Basic loss per share was USD 13.2 compared to USD 14.4 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +14.80% | 38.76M | |
| +7.56% | 111B | |
| +11.37% | 106B | |
| -12.39% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.79% | 16.81B | |
| +38.14% | 12.54B | |
| -24.38% | 8.09B |
ONCOCYTE CORPORATION 
